Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis I
Conditions
Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
Trial Timeline
Dec 1, 2004 → Jan 1, 2006
NCT ID
NCT00144781About Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) is a approved stage product being developed by Sanofi for Mucopolysaccharidosis I. The current trial status is completed. This product is registered under clinical trial identifier NCT00144781. Target conditions include Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome.
What happened to similar drugs?
4 of 14 similar drugs in Mucopolysaccharidosis I were approved
Approved (4) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00144781 | Approved | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Odiparcil | Inventiva | Phase 2 | 29 |
| anakinra | Swedish Orphan Biovitrum | Phase 1/2 | 32 |
| laronidase | Sanofi | Approved | 43 |
| Laronidase | Sanofi | Approved | 43 |
| Aldurazyme (Recombinant Human Alpha-L-Iduronidase) + Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Sanofi | Phase 2 | 35 |
| Laronidase + Cyclosporine A (CsA) + Azathioprine (Aza) | Sanofi | Phase 1/2 | 32 |
| Aldurazyme (Recombinant Human Alpha-L-Iduronidase) | Sanofi | Phase 3 | 40 |
| rhIDU (recombinant human-Alpha-L-Iduronidase) + Placebo | Sanofi | Phase 3 | 40 |
| Aldurazyme + Aldurazyme + placebo | Sanofi | Phase 3 | 40 |
| Laronidase | Sanofi | Approved | 35 |
| JR-141 | JCR Pharmaceuticals | Phase 2/3 | 38 |
| JR-441 + JR-441 + JR-441 | JCR Pharmaceuticals | Phase 1/2 | 36 |
| JR-446 | JCR Pharmaceuticals | Phase 1/2 | 39 |
| JR-171 | JCR Pharmaceuticals | Phase 1/2 | 32 |
| JR-141 | JCR Pharmaceuticals | Phase 2 | 39 |
| JR-141 + Idursulfase + JR-141 or Idursulfase | JCR Pharmaceuticals | Phase 3 | 44 |
| JR-141 | JCR Pharmaceuticals | Phase 3 | 47 |
| JR-171 (lepunafusp alfa) | JCR Pharmaceuticals | Phase 1/2 | 32 |
| JR-141 | JCR Pharmaceuticals | Phase 1/2 | 32 |
| JR-141 | JCR Pharmaceuticals | Phase 2/3 | 42 |